Iovance Biotherapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Iovance Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $12.8. The average 1-year stock price forecast is 9.95% lower than the current stock price, while the lowest is $6.00 (-57.79%) and the highest is $20 (+40.70%).

Price Target: $12.8 (-9.95%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$6.00	$12.8	$13.5	$20
Change	-57.79%	-9.95%	-5.03%	+40.70%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	6	6	6	5	5	6
Buy	2	2	2	2	2	2
Hold	3	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	10	10	9	9	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yanan Zhu Wells Fargo	Wells Fargo	Buy Maintains $14 → $18	Buy	Maintains	$14 → $18	+26.63%	Sep 30, 2026
Etzer Darout Barclays	Barclays	Buy Maintains $15	Buy	Maintains	$15	+5.52%	Sep 30, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $9 → $20	Buy	Reiterates	$9 → $20	+40.70%	Sep 29, 2026
Nicholas Lorusso TD Cowen	TD Cowen	Buy Maintains $10 → $16	Buy	Maintains	$10 → $16	+12.56%	Sep 29, 2026
Andrea Newkirk Goldman Sachs	Goldman Sachs	Buy Initiates $15	Buy	Initiates	$15	+5.52%	Sep 24, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

408.24M

from 263.50M

54.93%

from 263.50M

Revenue Next Year

575.24M

from 408.24M

40.91%

from 408.24M

EPS This Year

-0.46

from -1.09

EPS Next Year

-0.24

from -0.46

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	1.19M	164.07M	263.50M	408.24M
Revenue Growth	-	-	-	13,698.99%	60.60%	54.93%
Operating Income	-342.70M	-398.88M	-460.56M	-395.28M	-398.21M	-211.83M
Net Income	-342.25M	-395.89M	-444.04M	-372.18M	-390.98M	-202.22M
EPS	-	-	-	-	-1.09	-0.46
Free Cash Flow	-	-	-	-	-336.24M	-148.00M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	415.0M
Avg	408.2M
Low	391.9M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	57.5%
Avg	54.9%
Low	48.7%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.41
Avg	-0.46
Low	-0.50

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-